Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in Uncontrolled Allergic Asthma
NCT01716754Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 2 trial of ligelizumab in allergic asthma, sponsored by Novartis. Started Dec 2012; status: completed.
02
Drugs
ligelizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01716754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716754.